Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.  

Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.

The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).

Elderly patients treated with high doses of corticosteroids are bound to have multiple medical problems. But this was only recently quantified by researchers analyzing a a population-based cohort of biopsy-proven giant cell arteritis (GCA) patients in Southern Sweden.

Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.

Happy New Year!

A French multicenter study of primary Sjogren's syndrome (pSS) patients fulfilling the American–European Consensus Group criteria or enlarged American–European Consensus Group criteria were retrospectively studied based on having biopsy-proven renal involvement.

Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.

Dr. Jack Cush reviews highlights from this week on RheumNow.com

Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.

Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.

However, dementia is often not reported or studied in cohorts with neurologic disease in lupus. 

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

Dr. Cush highlights reports from this week on RheumNow.com.

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.

It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.

Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.